Literature DB >> 21092515

[Effect of FAM172A protein on apoptosis and proliferation in HEK293 cells].

Lian-xi Li1, Wen-bai Zhou, Zheng Tao, Wen-juan Deng, Wen-chang Liang, Zhi-hong Yang, Wei-wei Ye, Yu-qian Bao, Wei-ping Jia, Ren-ming Hu.   

Abstract

OBJECTIVE: To study the effect of FAM172A protein related to diabetic macroangiopathy on apoptosis and proliferation in HEK293 cells.
METHODS: The pDrive-FAM172A plasmid constructed in our previous study was used as a template to amplify human FAM172A open reading frame by a polymerase chain reaction. The resulting PCR products were subcloned into the eukaryotic expression vector PDC315 to construct recombinant PDC315-FAM172A plasmid. PDC315-FAM172A plasmid was identified by enzyme cleavage and sequencing analysis. HEK293 cells were transiently transfected respectively with appropriate PDC315 or PDC315-FAM172A plasmid by Lipofectamine 2000 according to the manufacturer's instruction. XTT assay and growth curve were used to observe the effect of over-expression of FAM172A gene on HEK293 cell proliferation. PI and Annexin V/PI staining method were used to assess the effect of FAM172A gene on apoptosis and cell cycle of HEK293 cell.
RESULTS: Eukaryotic expression vector PDC315-FAM172A was successfully constructed and identified by enzyme cleavage and sequencing analysis. Compared with PDC315 plasmid transfection, the XTT assay showed that optical density (A) value increased by 52% when transfected with PDC315-FAM172A plasmid (0.21±0.07 vs 0.32±0.06, P<0.01). Growth curve revealed that HEK293 cells transfected with PDC315-FAM172A plasmid proliferated faster than those transfected with PDC315 plasmid. PI staining showed that, as compared with PDC315 plasmid transfection, the apoptotic rate of HEK293 cells transfected with PDC315-FAM172A plasmid decreased by 38.5% (23.79±1.36 vs 14.64±0.95, P<0.01), cell percentage of G0-G1 phases significantly decreased (66.79±1.73 vs 58.16±0.75, P<0.01) and cell percentage of S phases significantly increased (22.62±1.16 vs 33.56±0.94, P<0.01). Annexin V/PI staining revealed that, as compared with PDC315 plasmid transfection, the percentage of early and advanced apoptotic cells decreased by 28% (13.63±0.56 vs 9.79±0.39, P<0.01) and 29% (7.70±0.29 vs 5.43±0.29, P<0.01) respectively.
CONCLUSION: FAM172A protein promotes cell proliferation, inhibits cell apoptosis and facilitates S-phases entry. It indicates that FAM172A protein is involved in cell growth regulation. Our findings provide a clue for further study on its physiological functions and roles in diabetic macroangiopathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21092515

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  4 in total

1.  Aberrant supracallosal longitudinal bundle: MR features, pathogenesis and associated clinical phenotype.

Authors:  Filippo Arrigoni; Romina Romaniello; Denis Peruzzo; Andrea Righini; Cecilia Parazzini; Paola Colombo; Maria Teresa Bassi; Fabio Triulzi; Renato Borgatti
Journal:  Eur Radiol       Date:  2015-11-11       Impact factor: 5.315

2.  The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism.

Authors:  Hong Zhao; Yujie Wang; Yufeng Liu; Xiaohua Hao; Hongshan Wei; Wen Xie
Journal:  Anal Cell Pathol (Amst)       Date:  2019-12-13       Impact factor: 2.916

3.  Population demographic history and population structure for Pakistani Nili-Ravi breeding bulls based on SNP genotyping to identify genomic regions associated with male effects for milk yield and body weight.

Authors:  Saher Islam; Umesh K Reddy; Purushothaman Natarajan; Venkata Lakshmi Abburi; Amna Arshad Bajwa; Muhammad Imran; Muhammad Yasir Zahoor; Muhammad Abdullah; Aamir Mehmood Bukhari; Sajid Iqbal; Kamran Ashraf; Asif Nadeem; Habibur Rehman; Imran Rashid; Wasim Shehzad
Journal:  PLoS One       Date:  2020-11-24       Impact factor: 3.240

4.  FAM172A affects cell proliferation and apoptosis not by targeting β-tubulin in HepG2 cells.

Authors:  Ai-Min Xu; Chuan-Jiang He; Zureguli Tuerxun; Abuduaini Anikezi
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.